Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Fuji
Medtronic
AstraZeneca
QuintilesIMS
Johnson and Johnson
Julphar
McKesson
Healthtrust
Dow

Generated: October 19, 2017

DrugPatentWatch Database Preview

Cppi Cv Company Profile

« Back to Dashboard

What is the competitive landscape for CPPI CV, and what generic alternatives to CPPI CV drugs are available?

CPPI CV has one approved drug.

There are three US patents protecting CPPI CV drugs.

There are sixty-eight patent family members on CPPI CV drugs in thirty-nine countries and twenty-one supplementary protection certificates in ten countries.

Summary for Applicant: Cppi Cv

International Patents:68
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-001Jan 26, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-001Jan 26, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► SubscribeYY ► Subscribe
Cppi Cv
SUTENT
sunitinib malate
CAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CPPI CV drugs

Drugname Dosage Strength Tradename Submissiondate
sunitinib malate
Capsules12.5 mg, 25 mg, 37.5 mg and 50 mg
SUTENT
1/26/2010

Non-Orange Book Patents for Cppi Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,572,924Pyrrole substituted 2-indolinone protein kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cppi Cv Drugs

Country Document Number Estimated Expiration
MexicoPA02008021► Subscribe
Hungary0204433► Subscribe
Japan2003523340► Subscribe
Portugal1255752► Subscribe
Costa Rica20120009► Subscribe
Eurasian Patent Organization005996► Subscribe
Bulgaria107078► Subscribe
Australia2001239770► Subscribe
Portugal1255536► Subscribe
Hungary228979► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cppi Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008000002Germany► SubscribePRODUCT NAME: SUNITINIB, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH VERTRAEGLICHEN SALZES, EINSCHLIESSLICH DES L-MALATSALZES; REGISTRATION NO/DATE: EU/1/06/347/001-003 20060719
1255752/02Switzerland► SubscribePRODUCT NAME: TOCERANIB; REGISTRATION NO/DATE: SWISSMEDIC 60121 09.07.2010
0332Netherlands► Subscribe
1255752/01Switzerland► SubscribePRODUCT NAME: SUNITINIB; REGISTRATION NUMBER/DATE: SWISSMEDIC 57563 28.04.2006
2010000004Germany► SubscribePRODUCT NAME: TOCERANIB UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/2/09/100/001-003 20090923
C004/2008Ireland► SubscribeSPC004/2008: 20081105, EXPIRES: 20210718
657Luxembourg► Subscribe91657, EXPIRES: 20240923
2010002,C1255752Lithuania► SubscribePRODUCT NAME: TOCERANIBUM; REGISTRATION NO/DATE: EU/2/09/100/001, 2009 09 23 EU/2/09/100/002, 2009 09 23 EU/2/09/100/003 20090923
2008 00015Denmark► Subscribe
2008002Lithuania► SubscribePRODUCT NAME: SUNITINIBUM; REG. NO/DATE: EU/1/06/347/001-003 20070808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Mallinckrodt
Baxter
McKesson
Merck
Federal Trade Commission
Johnson and Johnson
QuintilesIMS
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot